Literature DB >> 6095159

Pathogenesis of recurrent herpes simplex labialis. IV. Maturation of lesions within 8 hours after onset and implications for antiviral treatment.

S L Spruance, G Wenerstrom.   

Abstract

In order to define precisely the development of recurrent herpes simplex labialis, we studied 122 untreated or placebo-treated patients who were first seen when their lesions were less than 24 hours old. Subjects were divided into three groups with lesion ages of 0 to 8, 9 to 16, or 17 to 24 hours. Lesion pain, area, and virus titer were determined for each group at the time of the first clinic visit and again on the following day, and the change in lesion severity between visits was examined. The proportion of patients with increasing or decreasing lesion values was markedly influenced by lesion age. Among 0- to 8-hour-old lesions, area, pain, and virus titer increased in 27%, 21%, and 39% of the subjects, respectively, compared to 10%, 6%, and 0% among those lesions were 17 to 24 hours old at the first visit. A decrease in lesion area, pain, and virus titer was seen in 14%, 24%, and 12% of 0- to 8-hour-old lesions, compared with 35%, 65%, and 54% of the lesions in the 17- to 24-hour age group (p = 0.03, 0.006, and 0.0002). The majority of patients in each age group had mature lesions that remained unchanged or decreased in severity between visits. The possible benefits of antiviral chemotherapy to established lesions are limited because only a small number of untreated patients have progressive disease.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6095159     DOI: 10.1016/0030-4220(84)90031-8

Source DB:  PubMed          Journal:  Oral Surg Oral Med Oral Pathol        ISSN: 0030-4220


  9 in total

1.  High-dose, short-duration, early valacyclovir therapy for episodic treatment of cold sores: results of two randomized, placebo-controlled, multicenter studies.

Authors:  Spotswood L Spruance; Terry M Jones; Mark M Blatter; Mauricio Vargas-Cortes; Judy Barber; Joanne Hill; Donna Goldstein; Margaret Schultz
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

Review 2.  Novel composite efficacy measure to demonstrate the rationale and efficacy of combination antiviral-anti-inflammatory treatment for recurrent herpes simplex labialis.

Authors:  Christopher M Hull; Myron J Levin; Stephen K Tyring; Spotswood L Spruance
Journal:  Antimicrob Agents Chemother       Date:  2013-12-16       Impact factor: 5.191

3.  Pathogenesis of herpes simplex labialis: experimental induction of lesions with UV light.

Authors:  S L Spruance
Journal:  J Clin Microbiol       Date:  1985-09       Impact factor: 5.948

4.  Efficacy and safety of foscarnet for recurrent orolabial herpes: a multicentre randomized double-blind study.

Authors:  D Lawee; D Rosenthal; F Y Aoki; J Portnoy
Journal:  CMAJ       Date:  1988-02-15       Impact factor: 8.262

Review 5.  Famciclovir: a review of its use in herpes zoster and genital and orolabial herpes.

Authors:  Dene Simpson; Katherine A Lyseng-Williamson
Journal:  Drugs       Date:  2006       Impact factor: 9.546

6.  Comparison of topically applied 5-ethyl-2'-deoxyuridine and acyclovir in the treatment of cutaneous herpes simplex virus infection in guinea pigs.

Authors:  S L Spruance; D J Freeman; N V Sheth
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

7.  Failure of topical acyclovir in ointment to penetrate human skin.

Authors:  D J Freeman; N V Sheth; S L Spruance
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

8.  Acyclovir cream for treatment of herpes simplex labialis: results of two randomized, double-blind, vehicle-controlled, multicenter clinical trials.

Authors:  Spotswood L Spruance; Robert Nett; Thomas Marbury; Ray Wolff; James Johnson; Theodore Spaulding
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191

Review 9.  Single-day therapy: an expert opinion on a recent development for the episodic treatment of recurrent genital herpes.

Authors:  Stephen Tyring; Gary Richwald; Kamal Hamed
Journal:  Arch Gynecol Obstet       Date:  2006-09-07       Impact factor: 2.344

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.